Dr. Natasha C. Edwin
Claim this profileThedaCare Regional Cancer Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
8 reported clinical trials
17 drugs studied
Area of expertise
1Multiple Myeloma
Stage I
Stage II
Stage III
2Plasma Cell Neoplasms
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Natasha C. Edwin is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
More about Natasha C. Edwin
Clinical Trial Related5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Natasha C. Edwin has experience with
- Lenalidomide
- Dexamethasone
- Surgery
- Active Monitoring
- Daratumumab/rHuPH20
- Simplified Patient Care Strategy
Breakdown of trials Natasha C. Edwin has run
Multiple Myeloma
Plasma Cell Neoplasms
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Natasha C. Edwin specialize in?
Natasha C. Edwin focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved Stage I patients, or patients who are Stage II.
Is Natasha C. Edwin currently recruiting for clinical trials?
Yes, Natasha C. Edwin is currently recruiting for 3 clinical trials in Appleton Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Natasha C. Edwin has studied deeply?
Yes, Natasha C. Edwin has studied treatments such as Lenalidomide, Dexamethasone, Surgery.
What is the best way to schedule an appointment with Natasha C. Edwin?
Apply for one of the trials that Natasha C. Edwin is conducting.
What is the office address of Natasha C. Edwin?
The office of Natasha C. Edwin is located at: ThedaCare Regional Cancer Center, Appleton, Wisconsin 54911 United States. This is the address for their practice at the ThedaCare Regional Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.